Press release
Metastatic Castrate-resistant Prostate Cancer Market and Epidemiology Forecast 2032: Population Data, Drugs, Companies and Competitive Intelligence by DelveInsight | AstraZeneca, Tavanta Therapeutics, Veru Inc., Hinova Pharmaceuticals, Zenith Epigenetics
To Know in detail about the Metastatic Castrate-resistant Prostate Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Metastatic Castrate-resistant Prostate Cancer Market Forecast
https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Metastatic Castrate-resistant Prostate Cancer Market Report:
• The Metastatic Castrate-resistant Prostate Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• Prostate cancer prevalence in the 7MM was estimated to be over 7 million cases overall in 2022, and it is anticipated to rise during the study period (2019-2032)
• In terms of overall prevalent cases of 7MM, the US had the highest number of cases, with almost 3 million cases in 2022
• Germany had the highest diagnosed prevalence of prostate cancer among the EU4 nations, followed by France and Italy
• According to DelveInsight projections, there will be roughly 90,000 diagnosed prevalent cases of mCRPC in the seven key markets by 2022. The number of patients in the 7MM is anticipated to rise from 2019 to 2032, the study period.
• In the United States, the total number of diagnosed prevalent instances of mCRPC was estimated to be over 40,000 cases in 2022, and it is anticipated that this number will rise during the study period, which runs from 2019 to 2032.
• Key Metastatic Castrate-resistant Prostate Cancer Companies: AstraZeneca, Tavanta Therapeutics, Veru Inc., Hinova Pharmaceuticals, Zenith Epigenetics, Surface Oncology, Xencor, Cardiff Oncology, AstraZeneca, Regeneron Pharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, Fortis Therapeutics, Accutar Biotechnology, Hinova, Taiho Pharmaceuticals, and others
• Key Metastatic Castrate-resistant Prostate Cancer Therapies: Capivasertib, TAVT-45, VERU-111, HC-1119, ZEN-3694, SRF 617, Vudalimab, Onvansertib, AZD4635, REGN4336, TQB-3823, FOR46, AC0176, HP518, TAS3681, and others
• The Metastatic Castrate-resistant Prostate Cancer epidemiology based on age-specific cases analyzed that prostate cancer is more prevalent in people of age between 65-74 years followed by 55-64 years and 75-84 years
• The Metastatic Castrate-resistant Prostate Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Metastatic Castrate-resistant Prostate Cancer pipeline products will significantly revolutionize the Metastatic Castrate-resistant Prostate Cancer market dynamics.
Metastatic Castrate-resistant Prostate Cancer Overview
Metastatic CRPC has a poor prognosis and a lower survival rate. In comparison to men with localised prostate cancer, who have a 100% 5-year survival rate, men with metastatic prostate cancer have an estimated 5-year survival rate of roughly 30%.
Get a Free sample for the Metastatic Castrate-resistant Prostate Cancer Market Report
https://www.delveinsight.com/report-store/metastatic-castration-resistant-prostate-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Metastatic Castrate-resistant Prostate Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Metastatic Castrate-resistant Prostate Cancer Epidemiology Segmentation:
The Metastatic Castrate-resistant Prostate Cancer market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Metastatic Castrate-resistant Prostate Cancer
• Prevalent Cases of Metastatic Castrate-resistant Prostate Cancer by severity
• Gender-specific Prevalence of Metastatic Castrate-resistant Prostate Cancer
• Diagnosed Cases of Episodic and Chronic Metastatic Castrate-resistant Prostate Cancer
Download the report to understand which factors are driving Metastatic Castrate-resistant Prostate Cancer epidemiology trends @ Metastatic Castrate-resistant Prostate Cancer Epidemiology Forecast
https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Metastatic Castrate-resistant Prostate Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic Castrate-resistant Prostate Cancer market or expected to get launched during the study period. The analysis covers Metastatic Castrate-resistant Prostate Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Metastatic Castrate-resistant Prostate Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Metastatic Castrate-resistant Prostate Cancer Therapies and Key Companies
• Capivasertib: AstraZeneca
• TAVT-45: Tavanta Therapeutics
• VERU-111: Veru Inc.
• HC-1119: Hinova Pharmaceuticals
• ZEN-3694: Zenith Epigenetics
• SRF 617: Surface Oncology
• Vudalimab: Xencor
• Onvansertib: Cardiff Oncology
• AZD4635: AstraZeneca
• REGN4336: Regeneron Pharmaceuticals
• TQB-3823: Chia Tai Tianqing Pharmaceutical Group
• FOR46: Fortis Therapeutics
• AC0176: Accutar Biotechnology
• HP518: Hinova
• TAS3681: Taiho Pharmaceuticals
Discover more about therapies set to grab major Metastatic Castrate-resistant Prostate Cancer market share @ Metastatic Castrate-resistant Prostate Cancer Treatment Market
https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Scope of the Metastatic Castrate-resistant Prostate Cancer Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Metastatic Castrate-resistant Prostate Cancer Companies: AstraZeneca, Tavanta Therapeutics, Veru Inc., Hinova Pharmaceuticals, Zenith Epigenetics, Surface Oncology, Xencor, Cardiff Oncology, AstraZeneca, Regeneron Pharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, Fortis Therapeutics, Accutar Biotechnology, Hinova, Taiho Pharmaceuticals, and others
• Key Metastatic Castrate-resistant Prostate Cancer Therapies: Capivasertib, TAVT-45, VERU-111, HC-1119, ZEN-3694, SRF 617, Vudalimab, Onvansertib, AZD4635, REGN4336, TQB-3823, FOR46, AC0176, HP518, TAS3681, and others
• Metastatic Castrate-resistant Prostate Cancer Therapeutic Assessment: Metastatic Castrate-resistant Prostate Cancer current marketed and Metastatic Castrate-resistant Prostate Cancer emerging therapies
• Metastatic Castrate-resistant Prostate Cancer Market Dynamics: Metastatic Castrate-resistant Prostate Cancer market drivers and Metastatic Castrate-resistant Prostate Cancer market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Metastatic Castrate-resistant Prostate Cancer Unmet Needs, KOL's views, Analyst's views, Metastatic Castrate-resistant Prostate Cancer Market Access and Reimbursement
To know more about Metastatic Castrate-resistant Prostate Cancer companies working in the treatment market, visit @ Metastatic Castrate-resistant Prostate Cancer Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Metastatic Castrate-resistant Prostate Cancer Market Report Introduction
2. Executive Summary for Metastatic Castrate-resistant Prostate Cancer
3. SWOT analysis of Metastatic Castrate-resistant Prostate Cancer
4. Metastatic Castrate-resistant Prostate Cancer Patient Share (%) Overview at a Glance
5. Metastatic Castrate-resistant Prostate Cancer Market Overview at a Glance
6. Metastatic Castrate-resistant Prostate Cancer Disease Background and Overview
7. Metastatic Castrate-resistant Prostate Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Metastatic Castrate-resistant Prostate Cancer
9. Metastatic Castrate-resistant Prostate Cancer Current Treatment and Medical Practices
10. Metastatic Castrate-resistant Prostate Cancer Unmet Needs
11. Metastatic Castrate-resistant Prostate Cancer Emerging Therapies
12. Metastatic Castrate-resistant Prostate Cancer Market Outlook
13. Country-Wise Metastatic Castrate-resistant Prostate Cancer Market Analysis (2019-2032)
14. Metastatic Castrate-resistant Prostate Cancer Market Access and Reimbursement of Therapies
15. Metastatic Castrate-resistant Prostate Cancer Market Drivers
16. Metastatic Castrate-resistant Prostate Cancer Market Barriers
17. Metastatic Castrate-resistant Prostate Cancer Appendix
18. Metastatic Castrate-resistant Prostate Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Metastatic Castrate-resistant Prostate Cancer Pipeline https://www.delveinsight.com/report-store/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Metastatic Castrate-resistant Prostate Cancer Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Metastatic Castrate-resistant Prostate Cancer market. A detailed picture of the Metastatic Castrate-resistant Prostate Cancer pipeline landscape is provided, which includes the disease overview and Metastatic Castrate-resistant Prostate Cancer treatment guidelines.
Metastatic Castrate-resistant Prostate Cancer Epidemiology
https://www.delveinsight.com/report-store/metastatic-castration-resistant-prostate-cancer-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Metastatic Castrate-resistant Prostate Cancer Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Metastatic Castrate-resistant Prostate Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Herpes Simplex Virus Market
https://www.delveinsight.com/report-store/herpes-simplex-market
DelveInsight's "Herpes Simplex - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Herpes Simplex, historical and forecasted epidemiology as well as the Herpes Simplex market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Hypercoagulability Market
https://www.delveinsight.com/report-store/hypercoagulability-market
DelveInsight's "Hypercoagulability- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypercoagulability, historical and forecasted epidemiology as well as the Hypercoagulability market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Idiopathic Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/idiopathic-thrombocytopenic-purpura-market
DelveInsight's "Idiopathic Thrombocytopenic Purpura Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Idiopathic Thrombocytopenic Purpura, historical and forecasted epidemiology as well as the Idiopathic Thrombocytopenic Purpura market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Inguinal Hernia Market
https://www.delveinsight.com/report-store/inguinal-hernia-market
DelveInsight's "Inguinal Hernia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Inguinal Hernia, historical and forecasted epidemiology as well as the Inguinal Hernia market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Charcot-marie-tooth Disease Market
https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-market
DelveInsight's 'Charcot-Marie-Tooth Disease Market Insights, Epidemiology, and Market Forecast 2032' report deliver an in-depth understanding of the Charcot-Marie-Tooth Disease, historical and forecasted epidemiology as well as the Charcot-Marie-Tooth Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Castrate-resistant Prostate Cancer Market and Epidemiology Forecast 2032: Population Data, Drugs, Companies and Competitive Intelligence by DelveInsight | AstraZeneca, Tavanta Therapeutics, Veru Inc., Hinova Pharmaceuticals, Zenith Epigenetics here
News-ID: 3593415 • Views: …
More Releases from DelveIinsight Business Research
Advanced Renal Cell Carcinoma Market Report 2034: Epidemiology Data, Therapies, …
DelveInsight's "Advanced Renal Cell Carcinoma Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Antibody Drug Conjugates, historical and forecasted epidemiology as well as the Antibody Drug Conjugates market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Advanced Renal Cell Carcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Advanced Renal…
PCSK9 Inhibitors Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, PCSK9 Inhibitors pipeline constitutes 14+ key companies continuously working towards developing 14+ PCSK9 Inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"PCSK9 Inhibitors Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the PCSK9 Inhibitors Market.
The PCSK9…
Metastatic Prostate Cancer Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clin …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Metastatic Prostate Cancer pipeline constitutes 75+ key companies continuously working towards developing 75+ Metastatic Prostate Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Metastatic Prostate Cancer Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Prostate…
Bunion (Hallux Valgus) Market to Expand Significantly by 2034, States DelveInsig …
DelveInsight's "Bunion Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Bunion, historical and forecasted epidemiology as well as the Bunion market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Bunion market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bunion Market Forecast
https://www.delveinsight.com/sample-request/hallux-valgus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Bunion…
More Releases for Metastatic
Key Trends Reshaping the Metastatic Bone Disease Market: Advancements in Targete …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Metastatic Bone Disease Market Size Growth Forecast: What to Expect by 2025?
The market size for metastatic bone disease has seen a quick expansion in the past few years. This market will increase from a value of $17.14 billion in 2024 to $18.88 billion in 2025, with a compound…
Emerging Trends Influencing The Growth Of The Metastatic Urothelial Carcinoma Ma …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How Big Is the Metastatic Urothelial Carcinoma Market Size Expected to Be by 2034?
The market size for metastatic urothelial carcinoma has seen exponential growth recently. The market will expand from a worth of $1.18 billion in 2024 to $1.42 billion in 2025, with a compound annual growth rate (CAGR) of 20.2%.…
Key Influencer in the Metastatic Cancer Drugs Market 2025: Surging Prevalence Of …
How Are the key drivers contributing to the expansion of the metastatic cancer drugs market?
The escalation in the incidence of metastatic cancers will be a driving force for the expansion of the metastatic cancer drugs market. Metastatic cancer is a late-stage cancer that spreads across the body. As the number of metastatic cancer cases escalates, so does the creation of innovative drugs to treat various kinds of metastatic cancers. The…
Prominent Metastatic Breast Cancer Treatment Market Trend for 2025: Advancements …
Which drivers are expected to have the greatest impact on the over the metastatic breast cancer treatment market's growth?
The increasing occurrence of breast cancer is anticipated to boost the progression of the metastatic breast cancer treatment market. Breast cancer is a form of the disease that originates in the breast cells and is caused by abnormal cell growth in the breast, leading to the formation of a tumor. This alteration…
Major Force in the Metastatic Bone Disease Market 2025: Impact Of Bone Cancer Pr …
How Will the Metastatic Bone Disease Market Grow, and What Is the Projected Market Size?
The market size for metastatic bone disease has seen considerable growth in recent years. There is an expected increase from $17.14 billion in 2024 to $18.88 billion in 2025, with a compound annual growth rate (CAGR) of 10.1%. The substantial growth during the historical period can be credited to factors like rising aging population, heightened cancer…
Combination Therapy Strategies for Metastatic Cancer
Metastatic cancer, where cancer cells spread from the primary tumor to distant organs, presents significant treatment challenges. Combination therapy strategies have emerged as a powerful approach to enhance treatment efficacy, overcome resistance, and improve patient outcomes in metastatic cancer.
Download Report:
https://www.kuickresearch.com/report-cancer-antibody-combinations-therapy-cancer-antibody-combination-monoclonal-antibodies-combination-drug-conjugate-antibodies-combination
One of the primary goals of combination therapy in metastatic cancer is to target both the primary tumor and metastatic sites. This comprehensive approach can improve overall disease control…
